Biotechnology company Elicio Therapeutics, Inc. (ELTX) announced Monday that the Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) did not meet the pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population following the completion of standard locoregional therapy.
However, landmark analyses during active ELI-002 7P treatment indicated early treatment benefit.
The post-hoc landmark analyses showed a consistent about 14% absolute DFS benefit during active treatment at both 3 and 6 months, suggesting early clinical activity, with treatment-arm separation persisting through 9 months.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.